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O B J E C T I V E S This study aims to provide insight into cellular kinetics using molecular imaging after
different transplantation methods of bone marrow–derived mononuclear cells (MNCs) in a mouse model
of peripheral artery disease (PAD).
B A C KG ROUND MNC therapy is a promising treatment for PAD. Although clinical translation has
already been established, there is a lack of knowledge about cell behavior after transplantation and
about the mechanism whereby MNC therapy might ameliorate complaints of PAD.
METHOD S MNCs were isolated from F6 transgenic mice (FVB background) that express ﬁreﬂy luciferase
(Fluc) and green ﬂuorescence protein (GFP). Male FVB and C57Bl6 mice (n  50) underwent femoral artery
ligation and were randomized into 4 groups receiving the following: 1) single intramuscular (IM) injection of
2  106 MNCs; 2) 4 weekly IM injections of 5  105 MNCs; 3) 2  106 MNCs intravenously; and
4) phosphate-buffered saline as control. Cells were characterized by ﬂow cytometry and in vitro biolumines-
cence imaging (BLI). Cell survival, proliferation, and migration were monitored by in vivo BLI, which was
validated by ex vivo BLI, post-mortem immunohistochemistry, and ﬂow cytometry. Paw perfusion and
neovascularization was measured with laser Doppler perfusion imaging (LDPI) and histology, respectively.
R E S U L T S In vivo BLI revealed near-complete donor cell death 4 weeks after IM transplantation. After
intravenous transplantation, BLI revealed that cells migrated to the injured area in the limb, as well as to the
liver, spleen, and bone marrow. Ex vivo BLI showed presence of MNCs in the scar tissue and adductor muscle.
However, no signiﬁcant effects on neovascularization were observed, as monitored by LDPI and histology.
CONC L U S I O N S This is one of the ﬁrst studies to assess kinetics of transplanted MNCs in PAD
using in vivo molecular imaging. MNC survival is short-lived, MNCs do not preferentially home to injured
areas, and MNCs do not signiﬁcantly stimulate perfusion in this particular model. (J Am Coll Cardiol
Img 2012;5:46–55) © 2012 by the American College of Cardiology Foundation
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47eripheral artery disease (PAD) currently af-
fects more than 27 million North Americans
and Europeans and is associated with impaired
leg function and decreased quality of life, leading
o significant morbidity and mortality (1,2). Despite
variety of treatment options, including percutane-
us transluminal angioplasty, stenting, and bypass
urgery, a cluster of patients remain unresponsive to
herapy, a third of whom have no option other than
mputation (3).
See page 56
Recently, stem cell therapy has emerged from
bench to bedside as a treatment for end-stage PAD,
potentially offering a last option for revasculariza-
tion of the ischemic limb. Although results from
pre-clinical experiments using bone marrow–
derived mononuclear cells (MNCs) appear hopeful,
outcomes from clinical studies are divergent (4),
raising questions about cell behavior and mecha-
nisms of action involved in the benefits of stem cell
transplantation. Regarding cell behavior, 2 major
questions to be addressed are the potential lack of
donor cell survival after introduction into ischemic
target tissue and inadequate cell homing to the
injured area after systemic administration (5). Three
mechanisms have been proposed as explanations for
the results from cell transplantation thus far: donor
cell death might hamper a lasting scaffolding effect,
impair cell-induced neovascularization, and limit
the secretion of protective paracrine factors by the
transplanted cells.
To study stem cell behavior, one must be able to
monitor cell location, migration, proliferation, and
death. Recent proof-of-principle studies have dem-
onstrated the ability to track cell fate after cardiac
injections (5,6). In the present study, we monitor by
bioluminescence imaging (BLI) the presence of
MNCs after transplantation in mice with induced
hind limb ischemia. These experiments are de-
signed to answer critical questions regarding cell
survival and homing patterns to the affected leg, as
well as functional consequences of different trans-
plantation strategies.
M E T H O D S
Experimental animals. Animal study protocols were
approved by the Animal Research Committees
from both institutions (Stanford University and
Leiden University Medical Center). The donor
group for imaging experiments consisted of 8-week aold male F6 mice, which were bred on FVB
background and ubiquitously express green fluores-
cent protein (GFP) and firefly luciferase (Fluc)
reporter genes driven by a -actin promoter, as
reviously described (7). Recipient animals for these
xperiments consisted of syngeneic, male FVB mice
10 to 12 weeks old, Jackson Laboratories, Bar
arbor, Maine). Additionally, C57Bl6 mice were
sed (10 to 12 weeks old, Jackson Laboratories).
Preparation and characterization of MNCs. Please re-
er to the Online Appendix.
Characterization of MNCs by ﬂow cytometry. Please
refer to the Online Appendix.
In vivo optical BLI. BLI was performed using the
VIS 200 (Xenogen, Alameda, California) system.
or in vitro characterization of luciferase expres-
ion, cells were suspended in different quantities in
ml of phosphate-buffered saline (PBS). After
dministration of 10 l of D-Luciferin (43.5 g/
l), peak signals (photons/s/cm2/sr) from a fixed
egion of interest were evaluated and plot-
ed versus cell number. For in vivo exper-
ments, recipient mice were anesthetized
ith isoflurane, shaved, and placed in the
maging chamber. After acquisition of a
aseline image, mice were intraperitone-
lly injected with D-Luciferin (400 mg/kg
ody weight). Mice were imaged on post-
njection days 1, 3, 6, 9, 13, 20, and 27.
eak signals (photons/s/cm2/sr) from a
region of interest were evaluated as de-
scribed (7). For ex vivo experiments, ani-
mals were euthanized immediately after
the moment when peak signals were
achieved. The organs were rapidly explanted and
imaged according to the protocol described
previously.
Laser Doppler perfusion imaging. Neovascularization
as monitored by measurements of perfusion of the
ouse hind limbs at the level of the paws and was
erformed before, directly after, and weekly over a
eriod of 4 weeks after the surgical procedure with
aser Doppler perfusion imaging (LDPI) (Moor
nstruments, Axminster, United Kingdom) (8). To
ontrol for temperature variability during measure-
ents, all animals were kept in a double-glassed jar
lled with 37°C water, keeping environment tem-
erature at a constant level during the LDPI mea-
urements. Each animal served as its own control.
ventually, perfusion was expressed as a ratio of the
ow in the left (ischemic) to right (nonischemic)
aw. Before each LDPI measurement, mice were
A B B
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48midazolam (5 mg/kg, Roche, Woerden, the Neth-
erlands) and medetomidine (0.5 mg/kg, Orion
Corp., Espoo, Finland).
Surgical model for hind limb ischemia and cell injec-
tions. Before surgery, mice were anesthetized with
ither isoflurane (2%) or an intraperitoneal injection
f a combination of midazolam (5 mg/kg), medeto-
idine (0.5 mg/kg), and fentanyl (0.05 mg/kg,
anssen, Tilburg, the Netherlands). The effect of
NC injections was tested in 2 models of hind
imb ischemia: a single electrocoagulation model
nd a double electrocoagulation model (8). For
nilateral single electrocoagulation of the femoral
rtery, ischemia was created by an electrocoagula-
ion of the femoral artery just proximally to the
uperficial epigastric artery. Moreover, a double
lectrocoagulation was performed to create a larger
herapeutic window for assessment of possible ar-
eriogenesis (8). For this model, first an electroco-
gulation of the common iliac artery was per-
ormed, followed by an electrocoagulation of the
emoral artery. Subsequently, the skin was closed
sing 6-0 silk sutures. One day after operation, 40
l cell/PBS injections were given into the adductor
muscle, or 100 l cell/PBS solution was injected
into the tail vein. To compare the efficacy of a single
versus repeated injection with cells, FVB mice were
randomized into 3 groups: 1) single intramuscular
(IM) injection of 2 106 MNCs; 2) 4 repeated IM
injections of 5 105 MNCs; and 3) IM injection of
BS injection as control (n  10 per group). The
eason for using FVB mice in the first experiment
as to establish a clinically resembling model of
utologous cell transplantation as our F6 transgenic
onor mice, used for in vivo BLI, were bred on
VB background. In addition, to investigate the
unctional effects of intravenous (IV) MNC injec-
ion, C57Bl6 mice were randomized into 2 groups:
) single IV injection of 2  106 MNCs; and 2) IV
njection of PBS (n  10 per group). Additionally,
n order to investigate the impact of the surgical
odel, 8 FVB mice were randomized to undergo
ither electrocoagulation or suture ligation of the
emoral artery just proximally to the superficial
pigastric artery. Both groups received IM injec-
ions of 2  106 MNCs into the adductor muscle.
Subsequently, cell survival was monitored by BLI,
and paw perfusion was followed by LDPI for 4
weeks or until full restoration was achieved in either
group.
Ex vivo enzyme-linked immunosorbent assay for apop-
tosis on digested muscle. Please refer to the Onlineppendix.Ex vivo assays of reporter gene expression. To vali-
date in vivo BLI findings, the bone marrow was
collected as described earlier and assayed for GFP
expression by flow cytometry, as described
previously.
Post-mortem immunohistochemistry. Please refer to
he Online Appendix.
Statistical analysis. Please refer to the Online
Appendix.
R E S U L T S
Cell characterization. After isolation and Ficoll se-
ection, the MNC population showed subpopula-
ions of CD31, CD34, CD45, and Sca-1, but
minimal Flk-1 cells, representing hematopoietic
ut not early endothelial progenitors cells. More-
ver, the strong expression of CD11b, Gr-1, and
K 1.1, representative of macrophages, granulo-
ytes, and natural killer cells, respectively, indicated
he largely inflammatory character of this donor cell
opulation (Fig. 1A).
Reporter gene characterization. For tracing the cells
n an in vivo fashion by BLI, we first set out to
haracterize the expression of the reporter gene Fluc
n vitro. As suggested in Figure 1B, luciferase
xpression intensity increased concordantly with
ncreasing cell number. When maximal expression
er well was plotted versus the amount of cells, a
obust correlation was observed with an r2 value
qualing 0.97 (Fig. 1C). Thus BLI signal intensity
s closely representative of the amount of living cells
arrying the luciferase reporter gene. Moreover,
he activity of GFP in the donor-specific Fluc-
FP double-fusion reporter gene construct was
onfirmed by in vitro fluorescence microscopy
Fig. 1D).
Monitoring kinetics of transplanted MNCs by in vivo
BLI. After single transplantation of 2 106 MNCs,
a short-term post-transplant increase in BLI signal
from 6.6  1.5104 at day 1 to 8.9  2.5104
p/s/cm2/sr at day 3 (p  NS) indicated an increase
in cells in the adductor muscle region during the
first days. Thereafter, however, cell death resulted
in a rapid decrease in signal intensity down to
background level after 4 weeks (Fig. 2). A similar
cumulative dose of MNCs, divided in 4 weekly
doses of 5  105 MNCs, led to a relatively stable
presence of donor cells. No statistically significant
differences after 4 weeks (5.1  0.8  103 in single
vs. 5.7  0.3103 in multiple dose group; p  NS)
were detected.
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49Ex vivo postmortem localization of GFP -MNCs in the
schemic adductor muscles. Skeletal muscles of mice
reated with a single injection of 2  106 MNCs
and weekly injections of 5  105 MNCs were
harvested 28 days after hind limb ischemia induc-
tion. Dismal numbers of GFP MNCs were only
observed in the adductor muscle of mice that
received weekly injections of MNCs (Fig. 3). These
GFP-MNCs surrounded vessels within the mus-
le tissue, suggesting a role for these cells in
eovascularization. By contrast, GFP-MNCs
were not observed in the adductor muscles of mice
receiving a single injection of MNCs.
LDPI of blood ﬂow restoration after MNC transplanta-
tion in FVB mice. Single femoral artery electrocoag-
ulation resulted in a significant decrease in paw
perfusion when compared with the healthy right
hind limb (p  0.001 for all groups) (Fig. 4). Three
days after MNC transplantation, a trend toward
better flow recovery with increased MNC number
was observed, as the ischemic/nonischemic paw
perfusion ratios in the single 2  106 MNC and
4-weekly 5  105 MNC injection groups were 0.75 
0.07 and 0.67  0.07, respectively, as compared
Figure 1. Bone Marrow MNC Characterization
(A) Flow cytometric analysis after Ficoll-selection of bone marrow–d
dothelial progenitor cells (Sca-1, Flk-1) and high numbers of adult h
(CD45, CD11-b, Gr-1, NK-1.1) (axes present counts). (B) In vitro biolu
luciferase–expressing MNCs show (C) robust correlation with cell nu
sr. (D) In vitro ﬂuorescence microscopy conﬁrms the expression ofwith 0.62  0.07 in the PBS group (p  NS). tHowever, no significant differences were observed,
as robust recovery of paw perfusion was seen in all
groups by week 4.
Histological analyses of collateral formation. Figure 5
shows no significant differences in collateral density
and collateral size in the post-ischemic adductor
muscle after a single 2  106 MNC injection, 4
repeated 5  105 MNC injections, and PBS con-
rol, further confirming the lack of functional im-
rovement in LDPI results. As shown in Online
igure 1, treatment with both single 2  106
MNCs and 4 weekly 5  105 MNCs led to
ignificantly (p  0.03 and p  0.02, respectively)
ecreased amounts of fragmented DNA (mirroring
poptosis) as compared with the PBS group, which
ad an almost 3-fold higher expression than its
ealthy contralateral counterparts.
Monitoring cell homing in vivo after systemic MNC
injection. The initial BLI signals on day 0 (1 h after
V transplantation of MNCs) equaled background,
onfirming that the cells were spread throughout
he circulatory system (Fig. 6). No signs of reten-
ion in the pulmonary capillaries were observed, in
ontrast to previous studies using larger size cell
ed mononuclear cells (MNCs) indicates low numbers of stem/en-
atopoietic cells of a predominantly inﬂammatory phenotype
escence imaging (BLI) signals from various numbers of ﬁreﬂy
ers (r2  0.97). Scale bars represent BLI signal in photons/s/cm2/
n ﬂuorescent protein (GFP) by the donor cells.eriv
em
min
mbypes such as mesenchymal stem cells (9). Over
r. A
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50time, however, signal intensity increased due to
homing and migration to the injured area. In
addition, signals arose from the bone marrow,
spleen, and liver, suggesting homing patterns that
mimic endogenous myelomonocytic pathways (10).
Ex vivo conﬁrmation of in vivo patterns of cellular
kinetics. To validate and further specify the ob-
served in vivo findings after systemic MNC injec-
tion, organs were procured immediately after mice
were euthanized. As shown in Online Figure 2A,
BLI after dissection of the skin showed in situ
signals from liver, spleen, and the long bones
similar to in vivo results. However, the signals
Figure 2. MNC Survival After Intramuscular Injection Into the A
(A) In vivo BLI pictures of mice that received either a total of 2  1
tom panel) show that MNC survival is short-lived, as most of the si
of signals showed a somewhat more stable level of MNC presence
tical signiﬁcance. Scale bars represent BLI signal in photons/s/cm2/s
Figure 3. Immunohistochemistry of GFP-MNCs Within the Post
Representative pictures of anti–green ﬂuorescent protein (GFP) mu
5adductor muscle of mouse receiving weekly 5  10 MNC injections, shthat were previously observed from the injured
area in vivo were now largely concentrated in the
subcutaneous fat pad as well as in the femoral
bone. Indeed, when the different tissues were
explanted, low signal was seen from the adductor
muscle, whereas equally strong signals were ob-
served from the scarred skin, the subcutaneous fat
pad, and the bone marrow in the femoral bone.
Thus the ex vivo imaging results confirmed the
robust in vivo signals from liver and spleen.
Moreover, the presence of donor GFP-MNCs
in the bone marrow was validated with flow
cytometry (Online Fig. 2B). Taken together,
ctor Muscles of FVB Mice After Femoral Artery Ligation
NCs by single injection (top panel) or by weekly injections (bot-
intensity died off at 4 weeks after transplant. (B) Quantiﬁcation
r repeated injections, although the difference did not reach statis-
bbreviations as in Figure 1.
hemic Adductor Muscle
staining of (A) positive control slide (magniﬁcation 20), and (B)
ddu
06 M
gnal
afte-Isc
scle
owing 2 GFP cells near a blood vessel (magniﬁcation 40).
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51these experiments showed that BLI is a reliable
method to monitor MNC trafficking in an in vivo
environment and that homing to the injured area
was not limited to the adductor muscle, but also
occurred in more natural biological niches such as
marrow, liver, and spleen.
Monitoring effects of intravenously injected MNC
therapy. For the previous experiments, FVB mice
ere used in order to establish a clinically resem-
ling model of autologous cell transplantation in
hich the donor group consisted of transgenic FVB
ice expressing GFP-Fluc. However, we observed
robust endogenous restoration of paw perfusion in
hese FVB mice. Therefore, to investigate the
unctional effects of IV MNC injection, another
train of mice (C57Bl6) was used in combination
ith a double electrocoagulation to ensure a larger
herapeutic window (8). After double electrocoag-
lation of both the femoral and iliac arteries, the
schemic/nonischemic paw perfusion ratio de-
reased dramatically from an overall mean of 1.04
re-operatively to 0.04 post-operatively (p 
.0001). IV injection of MNCs was incapable of
Figure 4. LDPI of Ischemic Hind Limbs After Intramuscular MNC
(A) Graphic representation and (B) quantiﬁcation of paw perfusion
decreased perfusion in the affected left hind limbs as compared wi
recovery can be observed 3 days after ligation, no signiﬁcant differ
MNC  bone marrow–derived mononuclear cell; PBS  phosphateestoring paw perfusion significantly, with a ratio of.60 in the MNC group compared with 0.57 in the
BS group (p  NS) at 4 weeks post-operatively
Fig. 7).
Effect of electrocoagulation on paw perfusion andMNC
survival. Considerable differences exist between dif-
erent murine models of hind limb ischemia (8).
e next sought to determine whether the electro-
oagulation or suture ligation method would better
t the purposes of investigating the therapeutic
ffect of cell therapy. As outlined in Online Figure
, the suture ligation method did not result in a
rolongation of the therapeutic window, as there
ere no significant differences in LDPI, with fast
ecovery of paw perfusion within 1 week (0.97 
.10 vs. 0.62 0.08; pNS) (Online Figs. 3A and
B). Moreover, cell survival was not significantly
ifferent in both groups, with a trend toward an
ncreased early cell survival in the suture ligation
roup (p  NS) (Online Fig. 3C).
D I S C U S S I O N
This is one of the first studies to evaluate post-
erapy
aser Doppler perfusion imaging (LDPI) show a signiﬁcantly
e healthy paw. Although a dose-dependent trend toward faster
s were measured over a total time period of 28 days (*p  0.05).
fered saline.Th
by l
th th
encetransplant MNC behavior in a murine model of
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52PAD using in vivo molecular imaging techniques.
The main findings can be summarized as follows:
1) MNC survival after a single IM injection is
short-lived; 2) repeated MNC injections do not
provide a significantly prolonged cell survival;
3) homing of MNCs after IV injection is not
limited to the area of injury but other natural
niches; and 4) neither IM nor IV injection of
MNCs results in an improved blood flow recovery
after hind limb ischemia induction.
The clinical relevance of these findings is signif-
icant. Since the pioneering work of Tateishi-
Yuyama et al. (11), more than 25 clinical trials have
been registered on www.clinicaltrials.gov, using ei-
her IM or systemic injections into the ischemic leg.
lthough the findings from this first study raised
arly hopes, the initial positive outcomes have not
ince been confirmed by large randomized clinical
rials. The original hope for using progenitor cells
n regenerative medicine was to regenerate the
amaged tissue by forming new blood vessels (12),
keletal muscle (13), or even myocardium (14).
owever, as the true regenerative capacity has been
uestioned (15), and considering the dismal survival
apacity of MNCs and other progenitor cells in this
nd other studies (5), a more plausible explanation
Figure 5. Immunohistochemistry Analysis of Arteriogenesis Wit
Representative pictures of anti- smooth muscle staining in mice tr
injection, and (C) PBS injections as a control. Quantiﬁcation of (D) m
signiﬁcant differences between study groups (p  NS). Abbreviatioor a possible beneficial effect would be the secretionof protective cytokines, as suggested before (16).
Indeed, it has recently been shown that a more
profound angiogenic response can be achieved in
ischemic muscle by transplanting progenitor cells
overexpressing both vascular endothelial growth
factor and stromal-derived factor-1 (17). Alterna-
tively, and in order to achieve true regeneration, one
could switch to more specialized cell types rather
than whole MNCs. To this end, it has recently been
shown that embryonic stem cell–derived endothe-
lial cells can improve perfusion due to the favorable
effect of engraftment and biological activity (18).
Thus, in the future, it might be a feasible approach
to use a set of growth factors or specialized cells for
gene therapy or to use a combination of these 2
approaches.
Previous studies have assessed MNC function
and mechanism after transplantation into the
ischemic leg largely by using post-mortem histo-
logical techniques (19). However, this approach
requires that animals be euthanized, which in-
creases inter-animal variance and hampers longi-
tudinal studies of the same subject. Moreover, the
search for scant donor cells on histological slides
from all organs is extremely difficult and time-
consuming. As a consequence, these techniques
the Post-Ischemic Adductor Muscle
d with (A) single 2  106 MNC injection, (B) weekly 5  105 MNC
number of collaterals and (E) mean collateral size showed no
s in Figure 4.hin
eate
eanare less suitable for studying the kinetics of cells
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53through the body over time. To overcome these
limitations, here we were able to take advantage
of the double-fusion reporter construct carrying
Fluc and GFP to yield valuable insight into
longitudinal cell fate. By doing so, we were able
to track the spatiotemporal kinetics of MNC
homing, retention, and survival in a murine
model of PAD.
Interestingly, we observed a relatively limited
cell survival after IM injection in the adductor
muscle that was independent upon the vascular
occlusion method. After a short-term increase in
BLI signal up to day 3, a rapid decrease in BLI
signal intensity relative to background after 4
weeks was observed. The limited cell survival was
confirmed by the immunohistochemical staining,
against GFP cells. No MNCs were detected 28
days after a single 2  106 MNC injection with
an anti-GFP immunohistochemical staining,
whereas 1 week after the fourth transplantation of
5  105 MNCs, a small proportion of these cells
ould be found. These GFP-MNCs were pres-
nt near blood vessels, suggesting either a role in
eovascularization or that these cells preferred
eing adjacent to oxygenated blood. The dismal
urvival in the adductor muscle is interesting
ecause femoral artery ligation results in less pro-
Figure 6. In Vivo Visualization of Systemically Injected MNC by
(A,B) One day after left femoral artery ligation, 2  106 MNCs were
pictures and signal quantiﬁcation on multiple time points show tha
the body, cells then traveled to the injured area but also showed p
BLI signal in photons/s/cm2/sr (p  NS). Abbreviations as in Figureound ischemia in the adductor muscle as compared tith the gastrocnemius muscle. This suggests that
ven in a normoxic niche, MNCs require more
iologically attractive environments to be capable
f robust survival. This once again stresses the
eed for development of cell survival–augmenting
pproaches such as scaffolds or transduction of
ells with pro-survival factors.
Results from this study show that, after sys-
emic injection, MNCs migrated extensively to
he bone marrow, spleen, and liver. This pattern
ndicates that MNCs traveled to their natural
iological niches, as all of these organs play a role
n intramedullary and extramedullary hematopoi-
sis. Confirming this observation, our BLI find-
ngs are concordant with previous leukocyte scans
howing retention in the liver and spleen (20).
or future experiments, it will be important to
mprove homing to the ischemic muscles, which
ay increase angiogenic response as measured by
DPI. This could be realized in 2 ways: 1) improv-
ng the attractiveness of the target environment
ith stem cell mobilizer such as short hairpin
nockdown of prolyl hydroxylase and factor-
nhibiting hypoxia inducible factor (21); or 2) ma-
ipulating the cells to be more specifically guided.
n this respect, it might be a better approach to
solate a subset of the mononuclear fraction such as
cted via tail vein injection and monitored for 10 days. In vivo BLI
er an initial low signal period due to scattered MNCs throughout
rence for the liver, bone marrow, and spleen. Scale bars representBLI
inje
t aft
refehe CD14 expressing cells that are expected to
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54play a more active role in the restorative process
after ischemia (22).
Study limitations. First, GFP-MNCs were used in
he hind limb ischemia mouse model in order to
tudy post-ischemic neovascularization. It has been
uggested that GFP can elicit an immune response
23), which may influence collateral artery forma-
ion because this is an inflammatory driven process.
owever, the lack of any effect on post-ischemic
erfusion recovery or collateral artery formation at
he tissue level makes the interference of immuno-
enic GFP cells on arteriogenesis unlikely. Sec-
ond, the present report studied MNC behavior in
an acute model of hind limb ischemia. Clearly, this
model is not truly reflective of PAD, which is a
chronic disease. Unfortunately, a superior model
with more chronically occluded arteries is not avail-
able yet in mice.
C O N C L U S I O N S
Taken together, to our knowledge, this is one of the
Figure 7. Functional Results After Systemic MNC Injection After
(A) After ligation of both the femoral and iliac arteries, markedly de
Quantiﬁcation of paw perfusion revealed that systemic MNC injecti
than PBS treatment (p  NS). Abbreviations as in Figure 4.PAD in an in vivo fashion using molecular imaging
techniques. Results from this study highlight the
caution that should be taken when interpreting
results from experimental as well as clinical studies.
The poor survival and homing patterns warrant
further research that should aim for better retention
and increased biological activity of the cells in the
injured area. Additional research may make cell
therapy a more valuable option for treating end-
stage PAD, which is in urgent need of better
treatment alternatives. To this end, molecular im-
aging should be fully exploited to provide more
insight into the mechanisms of action for cell
therapy.
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For an expanded Methods section and supple-
mentary ﬁgures, please see the online version
of this article.
